This test is most useful if any of these apply to you.
Urinary D-arabinitol has been studied as a clue to invasive Candida infection, mainly in hospitalized people with cancer or weakened immune defenses. Some studies found useful early changes. Most measured the urine D-to-L arabinitol ratio, which differs from the creatinine-normalized D-arabinitol result reported here.
If you're investigating bloating or digestive symptoms after antibiotics, the evidence is much thinner. Available studies do not establish this result as a way to diagnose gut yeast overgrowth, determine whether Candida is causing your symptoms, or show that lowering the number improves your health. Its use for gut health and routine wellness screening remains exploratory.
Arabinitol exists in two mirror-image forms, D and L. Both occur in healthy human body fluids. Laboratory cultures show that Candida albicans, Candida tropicalis and Candida parapsilosis produce the D form. Its presence in urine is therefore compatible with Candida activity, but it isn't exclusive evidence of infection.
Candida glabrata and Candida krusei generally produce little or no D-arabinitol. These species are one reason an unremarkable result cannot rule out a Candida infection. Infections caused by species that produce it can also be missed.
This urine test reports D-arabinitol relative to creatinine. Creatinine is a waste product produced by muscle metabolism and excreted through the kidneys. Dividing by urine creatinine reduces the effect of how concentrated or dilute your sample is. It does not make the result independent of kidney function or changes in creatinine excretion.
The D-to-L ratio used in much of the hospital research divides D-arabinitol by L-arabinitol instead. Serum studies measure the compound in the liquid portion of blood. These measurements have different denominators or specimens, so their numerical results and diagnostic performance cannot be transferred directly to this urine test.
Invasive candidiasis involves infection of the bloodstream or internal tissues. It can be life-threatening and occurs mainly in people with substantial risk factors, including intensive care admission, chemotherapy, central venous catheters and major abdominal surgery.
Several older studies evaluated repeated urine D-to-L ratios in people with blood cancers and very low counts of infection-fighting white blood cells. Their results were promising in some settings and poor in others.
| Who Was Studied | Measurement | What Was Found |
|---|---|---|
| 61 hospitalized adults with blood cancers, with an additional healthy comparison group | Repeated urine D-to-L arabinitol ratios | Detected 88% of confirmed disseminated infections; 91% of comparison participants without disseminated infection tested negative. |
| 100 children with cancer | Repeated urine D-to-L arabinitol ratios | Detected all 10 confirmed invasive infections in this small study. Positive results also occurred without confirmed infection. |
| 104 adults with blood cancers receiving antifungals for unexplained fever | Urine D-to-L arabinitol ratios | Detected only one of five bloodstream infections. Several brief bloodstream infections were missed, and positive results often appeared late. |
These figures describe selected hospital populations and repeated testing with a different urine calculation. They are not accuracy estimates for a single creatinine-normalized result obtained during an outpatient gut-health evaluation.
Blood studies also found that performance depended on the population. A study measuring D-to-L ratios in serum detected about three quarters of bloodstream Candida infections in a subgroup with blood disorders and prolonged low white cell counts, but about four in ten across the broader study population. These serum findings cannot be used as detection rates for this urine test.
Blood cultures can miss invasive infections, particularly when infection is confined to internal tissues. That has driven research into additional fungal markers.
In the study of adults with blood cancers, 71% of those with subsequently confirmed disseminated infection already had an elevated urine D-to-L ratio when antifungal treatment began on suspicion. Confirmation followed the first elevated ratio by an average of about three weeks. Confirmation included culture or tissue findings, so this was not a three-week advantage over blood cultures in every case.
The later study that missed several bloodstream infections shows why this early-detection result cannot be treated as a dependable warning period. The studies also did not establish that using creatinine-normalized urinary D-arabinitol to guide care improves outcomes.
A study of people with cancer and bloodstream Candida infection measured D-arabinitol relative to creatinine in serum. Death occurred in 71% of those with persistently elevated or increasing values, compared with 18% of those whose values resolved or were never elevated. This was an observational association in a small subgroup. It does not provide a prognosis from your urine result or show that lowering the marker itself reduces the risk of death.
Candida can live in the digestive tract without causing disease. Finding it there does not establish that it explains bloating, abdominal discomfort or changes in bowel habits.
Research on small intestinal fungal overgrowth has used cultures of fluid collected directly from the small intestine. In one study of people with persistent digestive complaints, symptoms were similar whether or not bacterial or fungal overgrowth was found. Urinary D-arabinitol has not been established as a substitute for that evaluation.
There is no validated pattern in which a small urine elevation identifies gut overgrowth and a larger elevation identifies invasive infection. The result also cannot locate the source of the compound. A stool Candida result adds information about organisms present in stool, but it cannot by itself establish small intestinal overgrowth or show that yeast is causing your symptoms.
Repeated testing can show whether the measured value is reproducible or changing. The size of a change that represents meaningful improvement in gut health has not been established. A personal baseline does not solve the uncertainty about what caused an elevation, and a falling result alone does not establish that an infection has cleared.
Evidence-backed interventions that affect your D-Arabinitol level
D-Arabinitol is best interpreted alongside these tests.
D-Arabinitol is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers